# Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers

> **NCT04458805** · PHASE1 · COMPLETED · sponsor: **Landos Biopharma Inc.** · enrollment: 56 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** NX-13 250 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04458805
- **Lead sponsor:** Landos Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-10
- **Primary completion:** 2020-10-21
- **Final completion:** 2020-10-21
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04458805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04458805, "Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04458805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*